Search Results

Policy

USDA Approves Merck Animal Health’s NOBIVAC® NXT Canine Flu H3N2 – The First and Only RNA-Particle Technology Vaccine for Canine Influenza

Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA, announced the U.S. Department of Agriculture approval of NOBIVAC® NXT Canine Flu H3N2, a next-level solution to help safeguard dogs against the ongoing threat of canine influenza.

June 25, 2024

·

6 min read

Deals

Merck Animal Health to Acquire Elanco’s Aqua Business

Merck Animal Health announced that it has signed a definitive agreement to acquire the aqua business of Elanco Animal Health Incorporated for $1.3 billion in cash, consisting of an innovative portfolio of medicines and vaccines, nutritionals and supplements for aquatic species.

February 5, 2024

·

7 min read

Pharm Country

Merck Animal Health’s Fourth Veterinary Wellbeing Study Indicates Progress in Addressing Mental Health Challenges Among Veterinary Teams

Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA, released findings of its comprehensive Veterinary Wellbeing Study conducted in collaboration with the American Veterinary Medical Association.

January 15, 2024

·

12 min read

Press Releases

Merck Animal Health Announces Expansion of NOBIVAC® NXT Platform with the First and Only RNA-Particle Technology Vaccine for Feline Leukemia Virus

September 25, 2024

·

5 min read

Infusion bag and injection syringe in the blue background, 3d rendering. Digital drawing.

Clinical research

Merck’s Subcutaneous Keytruda Meets Expectations in Phase III

Analysts are split on whether the positive trial results will help Merck stem future Keytruda losses as the mega-blockbuster goes off patent in 2028.

November 19, 2024

·

2 min read

·

Annalee Armstrong

Vaccines

CDC Panel Recommends Merck and Pfizer Pneumococcal Vaccines for Adults Aged 50–64

The CDC’s Advisory Committee on Immunization Practices on Wednesday backed the use of Merck’s Capvaxive and Pfizer’s Prevnar 20 in adults between 50-64 years of age, opening a bigger market for the respective companies.

October 24, 2024

·

2 min read

·

Tristan Manalac

Press Releases

Elanco Animal Health Reports Third Quarter 2024 Results

November 7, 2024

·

35 min read

Feb 2, 2020 South San Francisco / CA / USA - Merck & Co. headquarters in Silicon Valley; Merck & Co. Inc. is an American multinational pharmaceutical company

Collaboration

Merck Hops Onto PD-1/VEGF Train, Committing up to $3B Plus in LaNova Deal

Despite recent enthusiasm around the PD-1/VEGF space, BMO Capital Markets analyst Evan Seigerman noted that Merck’s pact with LaNova Medicines is more “conservativism” on the pharma’s part than confirmatory of recent data in the drug class.

November 14, 2024

·

2 min read

·

Tristan Manalac

Earnings

Merck Lowers Full-Year Sales Guidance Despite Strong Overall Q3 Results

Offsetting Merck’s growth in the third quarter were disappointing revenues from its HPV vaccine Gardasil and type 2 diabetes pill Januvia, with the company on Thursday narrowing its 2024 sales and adjusted profit outlooks.

October 31, 2024

·

2 min read

·

Tristan Manalac

Press Releases

Merck to Participate in the Jefferies London Healthcare Conference

November 14, 2024

·

3 min read